Adolescent health briefKratom Use Among U.S. Adolescents: Analyses of the 2019 National Survey on Drug Use and Health
Section snippets
Methods
We analyzed the 2019 National Survey on Drug Use and Health (NSDUH), a series of yearly cross-sectional surveys designated to yield a representative sample of all U.S. noninstitutionalized individuals aged 12 years and above. The first time that the NSDUH survey included questions about kratom use was in 2019. Our nationally representative sample consisted of 13,397 adolescents aged 12–17 years. Approximately 1.9% of the total adolescent respondents had missing data on kratom use. A more
Sample description
Approximately half (50.9%) of the sample were males (Table 1). Almost a quarter (21.6%) had used alcohol in the past 12 months, 5.5% had used cigarette in the past 12 months, 13.5% had used cannabis in the past 12 months, 2.3% reported nonmedical use of pain relievers in the past 12 months, and 1.8% reported use of any stimulants in the past 12 months.
Kratom use and correlates
The lifetime prevalence of kratom use among this adolescent sample was .44% (95% CI .32–.60). Compared to adolescents who did not use cigarettes
Discussion
In 2019, approximately 68,000 adolescents in the U.S. used kratom. Prevalence estimates of lifetime and past 12-month kratom use among this representative sample of U.S. adolescents were about a third the prevalence observed among a nonprobabilistic sample of U.S. adults [11], and substantially lower than comparable estimates for lifetime kratom use (3.4%) among adolescents in Thailand, where kratom has been used historically [19]. In relation to use of other drugs for the same age group, in
Acknowledgments
This research was supported by the National Institute on Drug Abuse T32 training grant at the UF Substance Abuse Training Center in Public Health from the National Institutes of Health (T32DA035167, Cottler, PI) and Mentored Research Scientist Development Award (K01DA046715, Lopez-Quintero, PI). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. The corresponding author affirms that everyone who
References (23)
- et al.
The medicinal chemistry and neuropharmacology of kratom: A preliminary discussion of a promising medicinal plant and analysis of its potential for abuse
Neuropharmacology
(2018) - et al.
Ethnopharmacology of kratom and the Mitragyna alkaloids
J Ethnopharmacol
(1988) - et al.
Neurobiology of kratom and its main alkaloid mitragynine
Brain Res Bull
(2016) - et al.
Risk of death associated with kratom use compared to opioids
Prev Med
(2019) - et al.
Kratom as a substitute for opioids: Results from an online survey
Drug Alcohol Depend
(2019) Patterns of kratom use and health impact in the US-results from an online survey
Drug Alcohol Depend
(2017)- et al.
The internet market for kratom, an opioid alternative and variably legal recreational drug
Int J Drug Policy
(2020) - et al.
Substance use among high-school students in Southern Thailand: Trends over 3 years (2002–2004)
Drug Alcohol Depend
(2007) Statement from FDA Commissioner Scott Gottlieb, M.D., on the agency's scientific evidence on the presence of opioid compounds in kratom, underscoring its potential for abuse
Kratom (Mitragyna speciose korth)
Notes from the Field: Kratom (Mitragyna speciosa) exposures reported to poison centers - United States, 2010-2015
MMWR Morb Mortal Wkly Rep
Cited by (3)
Kratom availability in California vape shops
2023, Preventive Medicine ReportsKratom’s Emergence and Persistence Within the US Polydrug Epidemic
2023, Current Addiction ReportsDemographic and behavioral factors associated with kratom use among U.S. college students
2022, Journal of American College Health
Conflicts of interest: All authors have agreed to the content and submission and have no conflicts of interest.